Anaplastic lymphoma kinase (ALK) has been identified as an oncogenic driver in several cancers especially in NB and is considered a critical contributor for tumorigenesis and a promising therapeutic target of NB (Frentzel et al., 2017; Li et al., 2021a). This evidence concerns the gene ALK and neuroblastoma.